Leap Therapeutic Stock Price, News & Analysis

Leap Therapeutics (LPTX) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical trials. The company's Phase 2 DeFianCe study of sirexatamab showed promising results in colorectal cancer treatment, with a 32% higher overall response rate and 3.5-month longer progression-free survival in patients with high DKK1 levels.

Financial results show a net loss of $67.6 million for 2024, improved from $81.4 million in 2023. Research and development expenses decreased to $57.2 million from $73.2 million, while general and administrative expenses reduced to $12.8 million from $13.8 million. The company maintains $47.2 million in cash as of December 31, 2024.

The company sees a significant market opportunity, with approximately 30,000 second-line CRC patients in the US and 160,000 in the next 7 largest markets. Leap has engaged a financial advisor to explore business development opportunities for sirexatamab.

Leap Therapeutics (LPTX) has reported updated data from Part B of the DeFianCe study, evaluating sirexatamab in combination with bevacizumab and chemotherapy for colorectal cancer (CRC) treatment. The study showed significant improvements in multiple patient groups:

In patients with high DKK1 levels, the treatment demonstrated a 32% higher overall response rate (ORR) and 3.5-month longer progression-free survival (PFS). For patients without prior anti-VEGF therapy, results showed a 22% higher ORR and 2.6-month longer PFS.

The treatment combination was well-tolerated, and 34 patients remain on the sirexatamab experimental arm compared to 24 in the control arm. The company sees a substantial market opportunity, with approximately 30,000 second-line CRC patients in the US and 160,000 in the next 7 largest markets. Leap plans to proceed with a registrational Phase 3 trial and has engaged financial advisors to explore business development opportunities.

Leap Therapeutics (LPTX) has reported initial data from two clinical studies. In the DeFianCe study Part B, sirexatamab combination therapy showed a 35% objective response rate in second-line colorectal cancer patients, compared to 23% in the control arm. The drug demonstrated particularly strong results in patients with high DKK1 levels, achieving a 48% response rate in the upper quartile.

Key subgroups showed promising results: 51% response rate in anti-VEGF therapy-naive patients, 54% response rate in prior anti-EGFR therapy patients, and 43% response rate in RAS wildtype tumors. The company plans to proceed with Phase 3 registrational studies in second-line colorectal cancer.

However, in the DisTinGuish Part C study for gastric cancer, despite showing activity in biomarker populations, the results did not generate sufficient signals to advance to Phase 3 trials in gastric cancer.

Leap Therapeutics (LPTX), a biotechnology company specializing in targeted and immuno-oncology therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Douglas E. Onsi, the company's President and CEO, will deliver a corporate overview presentation on Wednesday, January 15, 2025, at 2:15 p.m. Pacific Time.

The presentation will be accessible through a live webcast on the Investors page of Leap Therapeutics' website. A replay of the presentation will be available for a time at https://investors.leaptx.com/.

Leap Therapeutics (Nasdaq: LPTX), a biotech company specializing in targeted and immuno-oncology therapeutics, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York. Douglas E. Onsi, President and CEO, will engage in a fireside chat scheduled for Wednesday, December 4, 2024, at 4:00 p.m. Eastern Time. The presentation will be accessible via live webcast on the company's investor relations website, with a replay available for time viewing.

Leap Therapeutics (LPTX) reported Q3 2024 financial results with a net loss of $18.2 million, compared to $13.7 million in Q3 2023. Research and development expenses increased to $14.9 million from $11.5 million year-over-year. The company completed enrollment in Part B of the Phase 2 DeFianCe study for DKN-01 in colorectal cancer with 188 patients, with data expected mid-2025. Patient follow-up continues in Part C of the DisTinGuish study with 170 patients, with data expected late 2024 or early 2025. Cash position stands at $62.8 million, expected to fund operations into Q2 2026.

Leap Therapeutics has completed enrollment of 188 patients in Part B of the DeFianCe study, evaluating DKN-01 for second-line treatment of advanced colorectal cancer (CRC). The study combines DKN-01, an anti-Dickkopf-1 antibody, with standard bevacizumab and chemotherapy. Dr. Cynthia Sirard, Chief Medical Officer, highlighted the enthusiasm for DKN-01's potential, citing encouraging data from Part A showing clinically meaningful response rates and durable tumor reductions.

The Phase 2, open-label, global study's primary endpoint is progression-free survival (PFS), with an additional focus on PFS in left-sided CRC patients. Secondary objectives include objective response rate, duration of response, and overall survival. Initial data from Part B is expected in mid 2025.

Leap Therapeutics (LPTX) reported Q2 2024 financial results, highlighting progress in its oncology pipeline. Key developments include:

1. Increased overall response rate (ORR) to 33% in the DeFianCe study for colorectal cancer.
2. Expanded Part B of DeFianCe study to 180 patients, with enrollment expected to complete by September 2024.
3. Ongoing patient follow-up in DisTinGuish study for gastroesophageal cancer, with data expected in Q4 2024 or early 2025.
4. Completed $40 million private placement with investors including Gilead Sciences.

Financial highlights: Net loss increased to $20.4 million, primarily due to higher R&D expenses of $17.9 million. Cash and cash equivalents stood at $78.5 million as of June 30, 2024, expected to fund operations into Q2 2026.

Leap Therapeutics, Inc. reported financial results for Q1 2024, highlighting a $40 million private placement financing, completion of enrollment in key studies, and positive clinical data. The company's cash runway extends to Q2 2026, with plans for continued program expansion and major clinical milestones. Financially, net loss decreased to $13.8 million, research and development expenses dropped, and cash and cash equivalents stood at $54.9 million at the end of March 2024.